WebNov 24, 2024 · An overview of the phase 3 OPTIMUM study involving ponesimod and how the reduction in MRI-based outcomes, including brain atrophy, is significant in supporting … WebDec 22, 2024 · Ofatumumab is a fully human anti-CD20 monoclonal antibody administered by monthly subcutaneous injection at home. It is indicated first-line for RMS, and was …
Sara N. King - Leadership Developer Principal - Optimum
WebOct 13, 2024 · “ The OPTIMUM subgroup analysis supports the principle of early treatment intervention with high potency therapies such as ponesimod, which aims to reduce relapse rates, improve patient outcomes... WebMay 9, 2024 · OPTIMUM is the first DMT trial to use a validated disease-specific fatigue measure (Fatigue Symptoms and Impacts Questionnaire: Relapsing Multiple Sclerosis [FSIQ-RMS]) as a prespecified endpoint and it showed … crystal ski entry requirements for italy
New Head-to-Head Phase 3 Study Data Show Ponesimod …
WebAug 1, 2024 · Multiple sclerosis (MS) is an inflammatory autoimmune disorder and the most common cause of non-traumatic disability in young adults. The Phase 3 OPTIMUM study evaluated the efficacy and safety of oral ponesimod, a selective sphingosine-1-phosphate (S1P) receptor 1 modulator, vs. teriflunomide in patients with relapsing multiple sclerosis … WebMar 31, 2024 · The study was conducted from April 2015-May 2024 in 162 centers across 28 countries in North America, Europe, Mexico, Israel, and Turkey — patients were stratified by use of MS DMTs in the last 2 years prior to randomization and baseline Expanded Disability Status Scale ( EDSS) score (≤3.5 or >3.5). WebSep 24, 2024 · Ludwig Kappos presented results of the OPTIMUM study, in which ponesimod was compared with teriflunomide for the treatment of relapsing–remitting MS in 1,113 patients. Ponesimod reduced the... crystal ski discount codes 2022